약물유전학 및 양전자방출단층촬영을 이용한 항암화학요법 및 분자표적치료에 대한 반응 예측

키워드

참고문헌 (112)

1. Lord RV, "Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non- small cell lung cancer", Clin Cancer Res, 8, pp.2286~2291 (2002)
2. Shirota Y, "ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy", J Clin Oncol, 19, pp.4298~4304 (2001)
3. Ceppi P, "ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced nonsmall- cell lung cancer treated with cisplatin and gemcitabine", Ann Oncol, 17, pp.1818~1825 (2006)
4. Yu JJ, "Comparison of two human ovarian carcinoma cell lines (A2780", CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene, 2000, pp.16, 555~560
5. Metzger R, "High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil", Clin Cancer Res, 4, pp.2371~2376 (1998)
6. Sturgis EM, "DNA repair gene ERCC1 and ERCC2", XPD polymorphisms and risk of squamous cell carcinoma of the head and neck, 2002, pp.128, 1084~1088
7. Chen P, "Association of an ERCC1 polymorphism with adult-onset glioma", Cancer Epidemiol Biomarkers Prev, 9, pp.843~847 (2000)
8. Stoehlmacher J, "A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU", oxaliplatin combination chemotherapy in refractory colorectal cancer, 2004, pp.91, 344~354
9. Park SY, "Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients", Med Oncol, 23, pp.489~498 (2006)
10. 강석범, "Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer", Experimental and Molecular Medicine, 38(3), pp.320~324 (2006), 생화학분자생물학회
11. Zhou W, "Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinumbased chemotherapy", Clin Cancer Res, 10, pp.4939~4943 (2004)
12. Zárate RN, "Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy", World J Gastroenterol, 12, pp.6032~6036 (2006)
13. Park DJ, "A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer", Cancer Res, 61, pp.8654~8658 (2001)
14. Quintela-Fandino M, "DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy", J Clin Oncol, 24, pp.4333~4339 (2006)
15. Gurubhagavatula S, "XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy", J Clin Oncol, 22, pp.2594~2601 (2004)
16. Weaver DA, "ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non- small cell lung cancer cell lines", Mol Cancer, 4, pp.18~ (2005)
17. Hu JJ, "Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity", Carcinogenesis, 22, pp.917~922 (2001)
18. Chung HH, "XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer", Gynecol Oncol, 103, pp.1031~1037 (2006)
19. Wu X, "Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer", J Clin Oncol, 24, pp.3789~3798 (2006)
20. Wang ZH, "Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer", Ai Zheng, 23, pp.865~868 (2004)
21. Beck WT, "Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations", Cancer Res, 56, pp.3010~3020 (1996)
22. Hille S, "Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer", Anticancer Drugs, 17, pp.1041~1044 (2006)
23. Tew KD, "Glutathione-associated enzymes in anticancer drug resistance", Cancer Res, 54, pp.4313~4320 (1994)
24. Beeghly A, "Glutathione Stransferase polymorphisms and ovarian cancer treatment and survival", Gynecol Oncol, 100, pp.330~337 (2006)
25. Goto S, "Overexpression of glutathione Stransferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells", Free Radic Res, 31, pp.549~558 (1999)
26. Shiga H, "and thymidylate synthase for neoadjuvant cisplatinbased chemotherapy in head and neck cancer", Clin Cancer Res, 5, pp.4097~4104 (1999)
27. Harries LW, "Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer", Carcinogenesis, 18, pp.641~644 (1997)
28. Medeiros R, "Platinum", paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome, 2003, pp.8, 156~161
29. Nagle CM, "The role of glutathione-S-transferase polymorphisms in ovarian cancer survival", Eur J Cancer, 43, pp.283~290 (2007)
30. Howells RE, "Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival", Int J Gynecol Cancer, 11, pp.107~112 (2001)
31. Kumar GN, "Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation", J Pharmacol Exp Ther, 268, pp.1160~1165 (1994)
32. Dai D, "Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid", Pharmacogenetics, 11, pp.597~607 (2001)
33. Gréen H, "mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T", A correlates with response to paclitaxel chemotherapy, 2006, pp.12(3 Pt 1), 854~859
34. Ichikawa W, "Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway", Gastric Cancer, 9, pp.145~155 (2006)
35. Horie N, "Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5’-terminal regulatory region of the human gene for thymidylate synthase", Cell Struct Funct, 20, pp.191~197 (1995)
36. Pullarkat ST, "Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy", Pharmacogenomics J, 1, pp.65~70 (2001)
37. Iacopetta B, "A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil", Br J Cancer, 85, pp.827~830 (2001)
38. Hitre E, "Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil", Pharmacogenet Genomics, 15, pp.723~730 (2005)
39. Kawakami K, "Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene", Cancer Res, 63, pp.6004~6007 (2003)
40. Mandola MV, "A novel single nucleotide polymorphism within the 5’tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity", Cancer Res, 63, pp.2898~2904 (2003)
41. Marcuello E, "Single nucleotide polymorphism in the 5’ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients", Int J Cancer, 112, pp.733~737 (2004)
42. Goekkurt E, "Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients", Br J Cancer, 94, pp.281~286 (2006)
43. Imyanitov EN, "Molecularbased choice of cancer therapy: realities and expectations", Clin Chim Acta, 379, pp.1~13 (2007)
44. Dervieux T, "Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications", Mutat Res, 573, pp.180~194 (2005)
45. Robert J, "Predicting drug response based on gene expression", Crit Rev Oncol Hematol, 51, pp.205~227 (2004)
46. Stöhlmacher J., "Pharmacogenetics in gastrointestinal tumors", Onkologie, 28, pp.435~440 (2005)
47. Jakobsen A, "Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity", J Clin Oncol, 23, pp.1365~1369 (2005)
48. Cohen V, "Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy", Clin Cancer Res, 9, pp.1611~1615 (2003)
49. Iyer L, "Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes", J Clin Invest, 101, pp.847~854 (1998)
50. Ando Y, "Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis", Cancer Res, 60, pp.6921~6926 (2000)
51. Carlini LE, "UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine", irinotecan, 2005, pp.11, 1226~1236
52. Singer CF, "Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition", Oncol Rep, 15, pp.353~359 (2006)
53. Deininger MW, "Optimizing therapy of chronic myeloid leukemia", Exp Hematol, 35(4), pp.144~154 (2007)
54. Sleijfer S, "Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment", Oncologist, 12, pp.719~726 (2007)
55. Heinrich MC, "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor", J Clin Oncol, 21, pp.4342~4349 (2003)
56. Heinrich MC, "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors", J Clin Oncol, 24, pp.4764~4774 (2006)
57. Debiec-Rychter M, "Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants", Gastroenterology, 128, pp.270~279 (2005)
58. Debiec-Rychter M, "KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours", Eur J Cancer, 42, pp.1093~1103 (2006)
59. Antonescu CR, "Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation", Clin Cancer Res, 11, pp.4182~4190 (2005)
60. Wardelmann E, "Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate", Clin Cancer Res, 12, pp.1743~1749 (2006)
61. Ciardiello F, "novel approach in the treatment of cancer: targeting the epidermal growth factor receptor", Clin Cancer Res, 7, pp.2958~2970 (2001)
62. Ciardiello F, "Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptorselective tyrosine kinase inhibitor", Clin Cancer Res, 6, pp.2053~2063 (2000)
63. Chakravarti A, "Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling", Cancer Res, 62, pp.200~207 (2002)
64. Bianco R, "Loss of PTEN", MMAC1, Oncogene, pp.2003, 22[DOI]
65. Li B, "Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas", Cancer Res, 63, pp.7443~7450 (2003)
66. She QB, "Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3’-kinase", Akt pathway signaling, 2003, pp.9, 4340~4346
67. Jones HE, "Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells", Endocr Relat Cancer, 11, pp.793~814 (2004)
68. Festuccia C, "Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines", Endocr Relat Cancer, 12, pp.983~998 (2005)
69. Ihle NT, "The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts", Mol Cancer Ther, 4, pp.1349~1357 (2005)
70. Lu Y, "Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)", J Natl Cancer Inst, 93, pp.1852~1857 (2001)
71. Slamon DJ, "Studies of the HER-2", neu proto-oncogene in human breast and ovarian cancer, 1989, pp.244, 707~712
72. Montemurro F, "Incorporating trastuzumab into the neoadjuvant treatment of HER2- overexpressing breast cancer", Clin Breast Cancer, 6, pp.77~80 (2005)
73. Montemurro F, "Trastuzumab- based combination therapy for breast cancer", Expert Opin Pharmacother, 5, pp.81~96 (2004)
74. Nagata Y, "PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients", Cancer Cell, 6, pp.117~127 (2004)
75. Valabrega G, "TGFalpha expression impairs Trastuzumab-induced HER2 downregulation", Oncogene, 24, pp.3002~3010 (2005)
76. Nagy P, "Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line", Cancer Res, 65, pp.473~482 (2005)
77. Kondo K, "Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters", Genes Chromosomes Cancer, 34, pp.58~68 (2002)
78. Rini BI, "Current status and future directions of molecular markers in renal cell carcinoma", Curr Opin Urol, 16, pp.332~336 (2006)
79. Weber WA, "Monitoring chemotherapy and radiotherapy of solid tumors", Eur J Nucl Med Mol Imaging, 33(Suppl 1), pp.27~37 (2006)
80. Honkoop AH, "Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer", Br J Cancer, 77, pp.621~626 (1998)
81. -fluorodeoxy-Dglucose to predict the pathologic response of breast cancer to primary chemotherapy, "J Clin Oncol", 2000, 1676~1688
82. Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer, "J Clin Oncol", 2000, 1689~1695
83. Dose Schwarz J, "Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET", J Nucl Med, 46, pp.1144~1150 (2005)
84. FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy, "Ann Oncol", 2004, 1352~1357
85. van de Wiele P, "Nuclear medicine imaging for prediction or early assessment of response to chemotherapy in patients suffering from breast carcinoma", Breast Cancer Res Treat, 72, pp.279~286 (2002)
86. Kim MK, "Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy", Eur J Cancer, 43, pp.1385~1391 (2007)
87. Stahl M, "Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus", J Clin Oncol, 23, pp.2310~2317 (2005)
88. Weber WA, "Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging", J Clin Oncol, 19, pp.3058~3065 (2001)
89. Wieder HA, "Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment", J Clin Oncol, 22, pp.900~908 (2004)
90. Song SY, "FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer", Int J Radiat Oncol Biol Phys, 63, pp.1053~1059 (2005)
91. Bombardieri E, "The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment", Eur J Nucl Med Mol Imaging, 33, pp.753~758 (2006)
92. Chao KS, "Functional imaging for early prediction of response to chemoradiotherapy: 3’-deoxy-3’-18F-fluorothymidine positron emission tomography--a clinical application model of esophageal cancer", Semin Oncol, 33(6 Suppl 11), pp.S59~S63 (2006)
93. Chao KS, "3’-deoxy-3’-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer", Semin Oncol, 34(2 Suppl 1), pp.S31~S36 (2007)
94. Kato H, "Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography", Anticancer Res, 27, pp.2627~2633 (2007)
95. Avril N, "Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced- stage ovarian cancer", J Clin Oncol, 23, pp.7445~7453 (2005)
96. Capirci C, "Sequential FDGPET", CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemoradiation therapy, 2007, pp.34, 1583~1593
97. Amthauer H, "Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology", Eur J Nucl Med Mol Imaging, 31, pp.811~819 (2004)
98. 3’-deoxy-3’-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer, "Eur J Nucl Med Mol Imaging", 2007, 878~883
99. Ott K, "Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial", J Clin Oncol, 21, pp.4604~4610 (2003)
100. -2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer, "J Clin Oncol", 2005, 8362~8370
101. Blasberg RG, "Prediction of brain tumor therapy response by PET", J Neurooncol, 22, pp.281~286 (1994)
102. Lee JK, "Usefulness of semiquantitative FDG-PET in the prediction of brain tumor treatment response to gamma knife radiosurgery", J Comput Assist Tomogr, 27, pp.525~529 (2003)
103. Kitagawa Y, "FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer", Eur J Nucl Med Mol Imaging, 30, pp.63~71 (2003)
104. Brun E, "Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET", Acta Oncol, 36, pp.741~747 (1997)
105. methionine-positron emission tomography, "Radiother Oncol", 1999, 225~232
106. Brun E, "FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma", Head Neck, 24, pp.127~135 (2002)
107. Yao M, "The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma", Int J Radiat Oncol Biol Phys, 59, pp.1001~1010 (2004)
108. Dimitrakopoulou-Strauss A, "Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma", J Nucl Med, 39, pp.1197~1202 (1998)
109. Maisey NR, "FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study", Br J Cancer, 83, pp.287~293 (2000)
110. FDG PET, "Br J Cancer", 2002, 506~511
111. FDG-PET, CT or MRI, and tumor marker, "Rofo", 2004, 76~84
112. Mikhaeel NG, "FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in highgrade non-Hodgkin lymphoma", Ann Oncol, 16, pp.1514~1523 (2005)

관련 논문AI추천